Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022
Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK cells by Innate’s Chief Scientific Officer, Eric Vivier, DVM, PhD, AstraZeneca-sponsored Phase 2 NeoCOAST study of neoadjuvant durvalumab alone or combined with novel agents, including monalizumab, in patients with … [Read more…]
